https://www.tevapharm.com/news-and-media/latest-news/teva-closes-acquisition-of-emalex-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advanci
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and...
https://www.businesswire.com/news/home/20260407152501/en/Emalex-Receives-U.S.-Patent-for-Orally-Disintegrating-Ecopipam-Formulation
Emalex Receives U.S. Patent for Orally Disintegrating Ecopipam Formulation
Emalex Biosciences received a patent covering an orally disintegrating tablet (ODT) formulation of ecopipam, an investigational D1 antagonist
u semalexreceivespatentorally